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Background: Prostate cancer is a frequently diagnosed malignancy in elderly men 
worldwide. Previously displayed as rare in Africa, but now a common diagnosis and a cause 
of mortality. 
Androgen deprivation therapy (ADT) is the main stay of treatment in Africa due to men 
presenting with advanced or metastatic disease. Men on androgen deprivation therapy will 
either develop androgen resistant prostate cancer and die of it or die of other causes. Men 
with prostate cancer on ADT have been found to have increased non cancer mortality and 
most of the excess mortality have been attributed to treatment. This study was aimed at 
evaluating the metabolic risk factors in men undergoing short term androgen deprivation 
therapy at Kilimanjaro Christian Medical Center (KCMC), Tanzania. 
Methods: This was a prospective cohort study, we evaluated 83 prostate cancer patients; 48 
on surgical castration, 9 medical castration (zoladex) and 26 were followed up with no 
treatment. Data analysis was done using stat version 12. Student 2 sided t tests was used to 
compare mean of the various variables between ADT group and none ADT group. 
Results: The mean age at diagnosis was 75±6.7 (55-95). The group of patients on ADT 
compared to the group of patients not on ADT had a statistically significant increase in all 
the lipid fractions i.e. low density lipoprotein(LDL), high density lipoprotein (HDL), 
cholesterol (CHOL), triglyceride (TGA) P=<0.001 at three and six month, fasting plasma 
glucose (P=<0.001) at three and six month, waist circumference P=0.02 and p=0.001 at 
three and six month respectively, compared to prostate cancer patients not on treatment. 
No patient in the six month had increments in serum and anthropometric parameter to 
meet the definition of a metabolic syndrome. 
Conclusion: Six month of androgen deprivation therapy is associated with a statistically 
significant increase in the fasting plasma glucose, lipid fractions, and waist circumference. 
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Introduction 
Prostate cancer (PCa) is a common malignancy in elderly men worldwide. In Africa PCa was 
previously displayed as rare, but now the world health organization approximates its 
prevalence at 4 % 1. There is a feeling that this is an under estimation, for example in Uganda it 
accounts for 39.2 per 100,000 men and 300 per 100,000 men in Nigeria, which approaches that 
of African American and Jamaica 2, 3. The greatest challenge for African urologists is an increase 
in the incidence of PCa, which is complicated by the fact that most patients present with 
advanced or metastatic disease. Therefore almost all our patients are palliated with androgen 
deprivation therapy (ADT). 
 
Men treated for PCa have profound hypogonadism which has been found to be an independent 
factor for cardiovascular disease and metabolic syndrome (MS) due to adverse lipid profile and 
increased fasting plasma glucose 4. Testosterone below normal range is associated withan 
increase cardiovascular risk factor. Diethylstilbestrol was the first to be used for medical ADT, 
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but was later found to be associated with cardiovascular toxicity in 30% of patients 5-6. Rosler 
and Witztum7 performed a prospective trial of ADT on sexual offenders and found out a 
decrease in bone mineral density, increase in insulin resistance, diabetes and worsening 
dyslipidemia. Twelve month of ADT in men with PCa has been associated with increase in all the 
lipid fractions and these changes were apparent at 3 months of treatment and permanent while 
patients continued ADT 8. 
 
Men with PCa on ADT have been found to have increased non cancer specific mortality and most 
of the excess mortality has been attributed to treatment 9. Having a MS before starting ADT has 
been associated with poor outcome compared to those without e.g. median time to PSA 
progression is 11 months vs. 32 month respectively, median overall survival for those with a MS 
was 40 month and forthose without metabolic syndrome the median time for overall survival 
was not reached due to the short time of follow up 10. 
 
Despite the dramatic clinical response to ADT, men undergoing ADT will either die of non 
cancer specific mortality approximated at 20% or will eventually develop castrate resistant PCa 
and die of the disease. There was a paucity of data on metabolic cardiovascular risks associated 
with ADT in our institution and very little data if any reported in the African setting. We 
evaluated metabolic cardiovascular risk factors in men undergoing short term ADT in our 
institution. 
 
Patients and Methods. 
   
This was prospective cohort study. It was conducted at KCMC consultation hospital, located in 
Moshi municipality in Tanzania, which serves an average of eleven million people. The study 
involved all patients newly diagnosed with PCa by histology, clinical stage III /IV who had been 
counseled and accepted ADT. The study protocol was approved by the Kilimanjaro Christian 
medical university ethics review committee. Excluded from the study were those patients who 
met the inclusion criteria but had cardiovascular and metabolic co-morbidity or factors that 
might affect serum lipid e.g. renal insufficiency (Cr> 120 Mmol/l) or hepatic disease, smoking 
and use of drugs such as thiazide diuretics. Patients who had serum lipid level of 
cholesterol>6.5mmol/l triglyceride (TGA)>1.7mmol/l low density lipoprotein (LDL)>5.44mm/l, 
fasting plasma glucose (FPG) >6.5mmol/l< blood pressure (BP)>135/85MmmHg, waist 
circumference102cm> and body mass index (BMI) >30kgm2> were excluded from the study. 
 
 Patients were divided into two groups, the ADT group consisted of patients who met the 
inclusion criteria, with clinical signs and symptoms sufficient to warrant immediate ADT/ 
(metastasis on lumbosacral x-ray, recurrent lower urinary tract obstruction after TURP, bone 
pain,) and those who we reluctant to differ treatment. The Non ADT group consisted of patients 
who fitted the inclusion criteria, with no sufficient signs and symptom to warrant immediate 
ADT and accepted to differ treatment until metastatic progression. Minimum time of follow up 
was six calendar months and maximum time of follow up fifteen month. Patients were 
instructed to fast for 12 hours the day before the intended visit using telephone. 
Anthropometric measurement of height and weight were taken simultaneously using a health O 
meter. Waist Circumference (WC) was taken using measuring tape with patient in full expiration 
in standing position at the level of the umbilicus as the smallest girth between the coastal 
margins and iliac crest. BP was taken using sypygomomanometer while the patient was in 
sitting position for 5 minutes. The same equipments were used consistently in all patients for all 
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Two fasting blood samples were collected from each consenting participant. The first 2 ml blood 
sample was collected in a tube containing sodium fluoride preservative for FPG estimation and 
second 4 ml blood sample was collected in a plain tube. All samples were transported in a cooler 
box from Urology ward to a Clinical laboratory for testing. Samples were centrifuged at 3000 
rpm for 5 minutes. Serum separated was stored at -20°C until analysis.  Samples were tested 
using Roche reagent kits for FPG, total CHOL, TGA’S, LDL and HDL on a COBAS Integra 400 plus 
auto-analyzer using enzymatic methods according to standard operating procedures. 
Calibration was done using Roche calibrators, and quality control sera from the manufacturer 
were tested alongside the test samples. 
 
A metabolic syndrome in this study was defined according to the adult treatment panel III , 
which say that an adult male is considered to have a metabolic syndrome if he has any three or 
more of the following , FPG>6.1Mmol/l, TGA>1.7Mmol/l, HDL< 1 Mmol/l , BP>135/85 and 
WC>102 cm. Data was analyzed using stat version 12; data were presented as mean + standard 
deviation frequencies or percentage. A student 2 sided t test was used to compare mean of the 




The period between January to December 2012, 115 men were histologically diagnosed with PC 
only 83 were recruited in the study as they met the inclusion criteria: 57 (68.7%) in the ADT 
and 26 (31.3%) in the non-ADT group. Table 1 shows the demographic characteristics of the 
patients. The mean age at diagnosis was 75±6.7 (55-95).  ADT consisted of surgical castration 
(bilateral orchiectomy) in 48 and medical castration (goserelin – Zoladex®) 3.5mg 
subcutaneous every month with 50mg of casodex for only 28 day at initiation of therapy in 9 
patients. The mean follow-up was 6 months (range 6 to 15 months). Seven patients in the ADT 
group died during the follow-up. No patients in the non-ADT group required ADT during the 
study period. The mean of the values of the various parameters of the ADT and Non ADT group 
did not reach that required for the definition of the metabolic syndrome, and no individual 
patient in the two groups had three or more parameters which met the definition of a metabolic 
syndrome during the study period (Table 2). Comparing the ADT and non-ADT groups at 3 and 
6 months, the mean change in waist circumference (WC) was significantly greater in the ADT 
group, but the blood pressure(BP), body mass index (BMI) and hemoglobin (Hb) did not differ 
significantly (Table 3).  
 





Non ADT group 
n=26(31%) 
Age (years)   
Mean (SD) 74.9(7.6) 75.6(7.8) 
Residence   
     Rural 26 14 
     Urban  30 12 
Family history of PCa    
     +ve  1 1 
      -ve  53 25 
Abbreviations: ADT -androgen deprivation therapy, SD-standard deviation 
PCa-prostate cancer  
Note -One patient data on address was not recorded. 
        -Three patient data on family history was not recorded. 
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Table 2. Summary of patient parameters before division into ADT and non ADT group 
Parameter Mean at diagnosis 
Age(Yrs.) 75  (55-95) 
Systolic BP (MmHg) 130  (100-132) 
LDL (Mmol/L)  2.6  (0.79-4.50) 
HDL (Mmol/l) 1.33  0.41(0.4-2.0) 
Chol (Mmol/l) 4.0  (0.25-6.50) 
TGA (Mmol/l) 0.95 0.39(0.07-1.02) 
Hb (Mmol/l) 11.25 2.16(9-16) 
BMI (kg/m2) 22.9  3.84(16-30) 
WC (cm) 82.0 13.77(27-100) 
FPG (Mmol/L) 3.9 0.47(2.2-5.0) 
Abbreviations: FPG-fasting plasma glucose, WC-Waist circumference,LDL- low density 
lipoprotein,HDL-high density lipoprotein,TGA-triglycerides,Hb-hemoglobin,BMI –body mass 
index BP-blood pressure, CHOL-cholesterol 
 
Table 3. Anthropometric and biochemical profile at 3 month of follow up. 





Characteristic  Mean(SD) Mean (SD) p-value 






BMI (KgM2). 23.4(3.5) 23.83(3.4) 
 
0.43 
Hemoglobin(g/dl) 11.41(1.9) 12.16(1.8) 
 
0.09 
LDL(Mmol/l) 3.38(1.01) 2.53(0.8) 
 
<0.001 
HDL(Mmol/ 1.52(0.5) 1.15(0.4) 
 
0.001 
TGA(Mmol/l) 1.5(0.6) 0.83(0.3) 
 
<0.001 
CHOL(Mmol/l) 5.01(1) 3.92(0.7) 
 
<0.001 
FPG(Mmol/l) 4.59(0.9) 3.87(0.5) 
 
<0.001 
Abbreviations: ADT-androgen deprivation therapy, BP-blood pressure, WC-waist 
circumference, LDL- low density lipoprotein, HDL -high density lipoprotein, TGA-triglycerides, 
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There was statistically significant increase in the mean change of all the serum lipid (LDL, DDL, 
CHOL and TGA) parameters between the two groups at three and six month P (<0.001).The 
difference in the mean of the FPG between the two groups was statistically significant at three 
and six month (p <0.001) (Table 4). 
 
Table 4. Anthropometric and biochemical profile at 6month of follow up. 
 ADT group ADT group  
 n=57(68%) N=26(32%)  
Characteristic  Mean(SD) Mean (SD) p-value 





87.24(10) 78.44(22) 0.01 
BMI(KgM2) 24.07(3.7) 24.42(3.5) 
 
0.69 





3.99(0.8) 2.83(1.1) <0.001 
HDL(Mmol/ 
 
1.81(0.5) 1.23(0.4) <0.001 









Abbreviations: ADT-androgen deprivation therapy, BP-blood pressure, WC-waist 
circumference, LDL- low density lipoprotein, HDL -high density lipoprotein, TGA-triglycerides, 




The mean age at diagnosis was 75±6.7; this was high compared to Mohamedali 11  who found 
that the average age at diagnosis was 68.9.This is mainly due to lack of screening in the Africa 
setting. Serum changes in the lipid fraction were statistically significant between the two groups 
at three and six month, this was similar to Braga (p <0.005) in a 12 month Crossectional study 
n=58 (20 ADT: 18 PCa after radiation therapy (XRP)/radical prostatectomy (RP): 20 normal 
elderly men).Though he obtained significant results his study was Crossectional and therefore 
difficult to ascertain temporal relationship, in homogeneous groups on XRT and RP which would 
have some influence on metabolism in some way 12. 
  
The current study had two homogenous groups in terms of serum and anthropometric 
parameters at inclusion, though we lacked a third group to cater for the effect of disease on 
metabolism. We were also able to demonstrate that these changes occur earlier than twelve 
month.  Mohamedali 11 did not demonstrate significant results in his twelve month case control 
prospective cohort n=75 (38 ADT: 37 non ADT) , though he had increases in serum parameters, 
this was mainly due to having a small group in the analysis after excluding a large number on 
cholesterol lowering drugs and some who were diabetic. 
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The increases in the lipid fractions in the current study are most likely due to ADT since similar 
results were not obtained in the non ADT group. There was a statistically significant increase in 
the FPG at three and six month of follow up in current study. Smith 8 was not able to 
demonstrate a statistically significant change in FPG in a twelve week prospective study of PCa 
patients on medical castration. This may not reflect the similar trend though this was a 
prospective study, is was somehow different from the current study since all of his patients 
were on medical castration and current study most of our patient were on surgical castration. 
He had a very small sample, a short time of follow up and lacked a comparison a group, might 
have affected his results. Despite of one patient developing diabetes within the twelve weeks, 
the change in glucose level was not statistically significant.  
 
From the finding of our study, patients on surgical castration may experience an early onset of 
hyperglycemia compared to medical castration. However Basaria et al13 were able to 
demonstrate a statistically significant increase in FPG level (p=0.002) in his cross sectional 
study of PCa patient on ADT for 12-101 month n=58 (18ADT:17XRT/RP: 18normal elderly). 
Moreover he had a third group of normal elderly men to cater for the effect of disease on 
metabolism, the controls he used had under gone RP / XRT this might in some way have 
confound his results, because RP and XRT may have some effects on metabolism. Since it was a 
cross sectional study, may present some difficult in determining temporal relationship. The 
result of our study could also have been confounded in some way due to lack of a third group to 
cater for the effect of age on metabolism. The increase in the FPG in the current study is most 
likely due to ADT since similar results were not demonstrated in the non ADT group. 
 
The mean change in waist circumference between the two groups was statistically significant at 
three and six month of follow up, similar finding was by Bragain his cross-sectional study 
involving PCa patient on ADT for 12 month compared with those on XRT and RP plus normal 
elderly men 12. The pattern may be different as he had significant results in his study which was 
a crossectional study and also had inhomogeneous group. The XRT and RP group could be 
considered in the normal elderly men since they were give a curative therapy and therefore 
cured, for this reason prostate cancer played a minimal role in metabolism. The current study 
results could also have been confounded in some way due to lack of a third group to cater for 




Six month of ADT use is associated with a statistically significant increase in the fasting plasma 
glucose, lipid fraction and WC, though none of the increases reached clinically significant level to 
require medical intervention. 
 
Recommendation 
From the results of this study it is important for urologist starting patients on ADT to obtain a 
baseline lipid fraction, Fasting plasma glucose, and anthropometric parameters before initiating 
ADT. It is also reasonable to follow up these parameters 6 monthly in those who had normal 
baseline serum biochemical characteristics and normal anthropometric parameters before 
starting ADT. We also recommend another prospective study to try and find out if these 
parameters actually reach a clinically significant level, when and which risk factors are 
responsible for early metabolic derangement. 
Study strength 
Only ADT naïve patients with normal biochemical and anthropometric measurements were 
included in this study, therefore the study gave a clear picture of the gradual changes in the 
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metabolic derangement during ADT. PCa patients on ADT were compared with PCa patients not 
on ADT to cancel out the effect of disease on metabolism, to allow only ADT play a role on 
metabolic changes. We included only black Africans in this study; therefore the effect of race did 
not affect the study result. 
 
Study limitations 
We were not able to measure testosterone during the study period; therefore study could not 
demonstrate castrate levels of testosterone in the study subjects.All our patients were on 
minimal androgen blockade this may have confounded the true picture in some way. Short 
follow up period in some way might have had affected on the study results. 
 
We did not have a third comparative group to cancel out the effect of age on metabolism. The 
number of patients in the treatment arm did not balance exactly those in the non treatment 
arm; therefore the study may have overestimated some of the parameters. Patients were also 
randomly assign to the two groups. 
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